These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37233774)

  • 41. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
    Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
    Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.
    Ismael O; Shimada A; Hama A; Sakaguchi H; Doisaki S; Muramatsu H; Yoshida N; Ito M; Takahashi Y; Akita N; Sunami S; Ohtsuka Y; Asada Y; Fujisaki H; Kojima S
    Pediatr Blood Cancer; 2012 Sep; 59(3):530-5. PubMed ID: 22106054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Analysis of risk factors for thromboembolism in patients with JAK2
    Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
    [No Abstract]   [Full Text] [Related]  

  • 46. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
    Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
    Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
    Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
    Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM; Schouten HC; van Marion AM
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
    Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.
    Van Egeren D; Kamaz B; Liu S; Nguyen M; Reilly CR; Kalyva M; DeAngelo DJ; Galinsky I; Wadleigh M; Winer ES; Luskin MR; Stone RM; Garcia JS; Hobbs GS; Michor F; Cortes-Ciriano I; Mullally A; Hormoz S
    Exp Hematol; 2022 Mar; 107():14-19. PubMed ID: 34921959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
    Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
    Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.